Abstract
A study of induced antibiotic tolerance of clinical isolates Klebsiella pneumoniae sensitive to meropenem and amikacin revealed the formation of phenotypically heterogeneous persisters in them, represented by the SCV (small colony variant) and NCV (normal colony variant) forms. There was no correlation of persister formation between these antimicrobial drugs (R=-0.37), which indicates different mechanisms of tolerance to antibiotics. The ability of amikacin to induce the formation of SCV persisters was higher than that of meropenem (p-level > 0.05), and the synergistic effect of both drugs contributed to a decrease in their number, to a maximum of 80.0%. At the same time, SCV-persists of K.pneumoniae were characterized by a short-term increase in adaptive resistance to antibiotics, which were used as inducers of the formation of persistent bacterium fractions (p-level > 0.05), which may contribute to their more effective survival in media with antibiotics.
Highlights
Èññëåäîâàíèå èíäóöèðîâàííîé àíòèáèîòèêîëåðàíòíîñòè ÷óâñòâèòåëüíûõ ê ìåðîïåíåìó è àìèêàöèíó êëèíè÷åñêèõ èçîëÿòîâ Klebsiella pneumoniae âûÿâèëî ôîðìèðîâàíèå ó íèõ ôåíîòèïè÷åñêè ãåòåðîãåííûõ ïåðñèñòåðîâ, ïðåäñòàâëåííûõ SCV è NCV ôîðìàìè
A study of induced antibiotic tolerance of clinical isolates Klebsiella pneumoniae sensitive to meropenem and amikacin revealed the formation of phenotypically heterogeneous persisters in them, represented by the SCV and NCV forms
There was no correlation of persister formation between these antimicrobial drugs (R=–0.37), which indicates different mechanisms of tolerance to antibiotics
Summary
Èññëåäîâàíèå èíäóöèðîâàííîé àíòèáèîòèêîëåðàíòíîñòè ÷óâñòâèòåëüíûõ ê ìåðîïåíåìó è àìèêàöèíó êëèíè÷åñêèõ èçîëÿòîâ Klebsiella pneumoniae âûÿâèëî ôîðìèðîâàíèå ó íèõ ôåíîòèïè÷åñêè ãåòåðîãåííûõ ïåðñèñòåðîâ, ïðåäñòàâëåííûõ SCV (small colony variant) è NCV (normal colony variant) ôîðìàìè. Ïðè ýòîì SCV-ïåðñèñòåðû K.pneumoniae õàðàêòåðèçîâàëèñü êðàòêîâðåìåííûì ïîâûøåíèåì àäàïòèâíîé óñòîé÷èâîñòè ê àíòèáèîòèêàì, êîòîðûå áûëè èñïîëüçîâàíû â êà÷åñòâå èíäóêòîðîâ îáðàçîâàíèÿ ïåðñèñòèðóþùèõ ôðàêöèé áàêòåðèèé (p
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
